Toll Free: 1-888-928-9744

Uveal Melanoma - Pipeline Review, H2 2017

Published: Oct, 2017 | Pages: 155 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Uveal Melanoma - Pipeline Review, H2 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Uveal Melanoma - Pipeline Review, H2 2017, provides an overview of the Uveal Melanoma (Oncology) pipeline landscape.

Uveal melanoma, the most common intraocular tumor, is a disease in which cancer (malignant) cells are found in the part of the eye called the uvea. The uvea contains cells called melanocytes. When these cells become cancerous, the cancer is called a melanoma. Symptoms include dark spot on the iris, glaucoma, eye pain and eye redness. Uveal melanoma is more common in people who have atypical mole syndrome, dysplastic nevus syndrome, and ocular or oculodermal melanocytosis. Treatment includes surgery, radiation and proton therapy. 

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Uveal Melanoma - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Uveal Melanoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Uveal Melanoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Uveal Melanoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 1, 9, 8, 1 and 6 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Preclinical and Discovery stages comprises 1, 1, 1 and 1 molecules, respectively.

Uveal Melanoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Uveal Melanoma (Oncology).
- The pipeline guide reviews pipeline therapeutics for Uveal Melanoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources. 
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Uveal Melanoma (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Uveal Melanoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects. 
- The pipeline guide reviews latest news related to pipeline therapeutics for Uveal Melanoma (Oncology)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Uveal Melanoma (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Uveal Melanoma (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
 Table of Contents
Table of Contents 2 List of Tables 3 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Uveal Melanoma - Overview 6 Uveal Melanoma - Therapeutics Development 7 Pipeline Overview 7 Pipeline by Companies 8 Pipeline by Universities/Institutes 11 Products under Development by Companies 12 Products under Development by Universities/Institutes 14 Uveal Melanoma - Therapeutics Assessment 15 Assessment by Target 15 Assessment by Mechanism of Action 18 Assessment by Route of Administration 21 Assessment by Molecule Type 23 Uveal Melanoma - Companies Involved in Therapeutics Development 25 Aeglea BioTherapeutics Inc 25 Bellicum Pharmaceuticals Inc 25 Bristol-Myers Squibb Co 26 Celldex Therapeutics Inc 26 Cleveland BioLabs Inc 27 Delcath Systems Inc 27 Eli Lilly and Co 28 Iconic Therapeutics Inc 28 Immunocore Ltd 29 Iovance Biotherapeutics Inc 29 Navigen Inc 29 Novartis AG 30 PEP-Therapy SAS 30 Pfizer Inc 31 Polaris Pharmaceuticals Inc 31 Spectrum Pharmaceuticals Inc 32 Syndax Pharmaceuticals Inc 32 Tesaro Inc 32 Uveal Melanoma - Drug Profiles 34 AEB-1102 - Drug Profile 34 AU-011 - Drug Profile 38 BPX-701 - Drug Profile 40 Cellular Immunotherapy for Metastatic Uveal Melanoma - Drug Profile 42 Cellular Immunotherapy to Target Melan-A, MAGE-3 and Survivin for Melanoma and Uveal Melanoma - Drug Profile 43 crizotinib - Drug Profile 44 emibetuzumab - Drug Profile 51 entinostat - Drug Profile 54 entolimod - Drug Profile 62 glembatumumab vedotin - Drug Profile 69 hI-con1 - Drug Profile 75 HPH-196 - Drug Profile 77 HPH-211 - Drug Profile 78 IMCgp-100 - Drug Profile 79 ipilimumab + nivolumab - Drug Profile 83 KCN-1 - Drug Profile 92 LXS-196 - Drug Profile 93 melphalan - Drug Profile 94 merestinib - Drug Profile 100 NAV-2729 - Drug Profile 102 niraparib - Drug Profile 104 nutlin-3 - Drug Profile 113 pasireotide ER - Drug Profile 114 pegargiminase - Drug Profile 117 PEP-010 - Drug Profile 126 sotrastaurin acetate - Drug Profile 127 sunitinib malate - Drug Profile 129 Vaccine for Oncology - Drug Profile 135 vincristine sulfate - Drug Profile 136 Uveal Melanoma - Dormant Projects 142 Uveal Melanoma - Discontinued Products 143 Uveal Melanoma - Product Development Milestones 144 Featured News & Press Releases 144 Appendix 152 Methodology 152 Coverage 152 Secondary Research 152 Primary Research 152 Expert Panel Validation 152 Contact Us 152 Disclaimer 153
List of Tables
Number of Products under Development for Uveal Melanoma, H2 2017 Number of Products under Development by Companies, H2 2017 Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017 Number of Products under Development by Universities/Institutes, H2 2017 Products under Development by Companies, H2 2017 Products under Development by Companies, H2 2017 (Contd..1), H2 2017 Products under Development by Universities/Institutes, H2 2017 Number of Products by Stage and Target, H2 2017 Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017 Number of Products by Stage and Mechanism of Action, H2 2017 Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017 Number of Products by Stage and Route of Administration, H2 2017 Number of Products by Stage and Molecule Type, H2 2017 Uveal Melanoma - Pipeline by Aeglea BioTherapeutics Inc, H2 2017 Uveal Melanoma - Pipeline by Bellicum Pharmaceuticals Inc, H2 2017 Uveal Melanoma - Pipeline by Bristol-Myers Squibb Co, H2 2017 Uveal Melanoma - Pipeline by Celldex Therapeutics Inc, H2 2017 Uveal Melanoma - Pipeline by Cleveland BioLabs Inc, H2 2017 Uveal Melanoma - Pipeline by Delcath Systems Inc, H2 2017 Uveal Melanoma - Pipeline by Eli Lilly and Co, H2 2017 Uveal Melanoma - Pipeline by Iconic Therapeutics Inc, H2 2017 Uveal Melanoma - Pipeline by Immunocore Ltd, H2 2017 Uveal Melanoma - Pipeline by Iovance Biotherapeutics Inc, H2 2017 Uveal Melanoma - Pipeline by Navigen Inc, H2 2017 Uveal Melanoma - Pipeline by Novartis AG, H2 2017 Uveal Melanoma - Pipeline by PEP-Therapy SAS, H2 2017 Uveal Melanoma - Pipeline by Pfizer Inc, H2 2017 Uveal Melanoma - Pipeline by Polaris Pharmaceuticals Inc, H2 2017 Uveal Melanoma - Pipeline by Spectrum Pharmaceuticals Inc, H2 2017 Uveal Melanoma - Pipeline by Syndax Pharmaceuticals Inc, H2 2017 Uveal Melanoma - Pipeline by Tesaro Inc, H2 2017 Uveal Melanoma - Dormant Projects, H2 2017 Uveal Melanoma - Discontinued Products, H2 2017



To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $2000
Multi User - US $4000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify